Pulmonary Drugs Market by Drug Class (Anticholinergics, Antihistamines, Combination Drugs, Inhaled Corticosteroids, Long-Acting Beta2-Agonists, Short-Acting Beta2-Agonists, Vasodilators, Antibiotics, Antileukotrienes, Enzymes, MAbs), Application (Allergic Rhinitis, Asthma & COPD, Cystic Fibrosis, Pulmonary Arterial Hypertension, Others), Distribution Channel (Drug Stores, E-commerce, Hospital Pharmacies, Retail Pharmacies) and Forecast 2017-2021

Pulmonary Drugs Market by Drug Class (Anticholinergics, Antihistamines, Combination Drugs, Inhaled Corticosteroids, Long-Acting Beta2-Agonists, Short-Acting Beta2-Agonists, Vasodilators, Antibiotics, Antileukotrienes, Enzymes, MAbs), Application (Allergic Rhinitis, Asthma & COPD, Cystic Fibrosis, Pulmonary Arterial Hypertension, Others), Distribution Channel (Drug Stores, E-commerce, Hospital Pharmacies, Retail Pharmacies) and Forecast 2017-2021

The global pulmonary drugs market segmentation is based on drug class (anticholinergics, antihistamines, combination drugs, inhaled corticosteroids, long-acting beta2-agonists, short-acting beta2-agonists, vasodilators, antibiotics, antileukotrienes, enzymes, MAbs), application (allergic rhinitis, asthma & COPD, cystic fibrosis, pulmonary arterial hypertension, others), distribution channel (drug stores, e-commerce, hospital pharmacies, retail pharmacies).

The global pulmonary drugs market report provides market size (Revenue USD Million 2014 to 2021), market share, trends and forecasts growth trends (CAGR%, 2017 to 2021). The global pulmonary drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. The global pulmonary drugs market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and also tracks the major competitors operating in the market by company overview, financial snapshot, key products, technologies and services offered, market share analysis and recent trends in the global market.

Major players operating in the global pulmonary drugs market and profiled in this report include Actelion Pharmaceuticals, Inc., AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Merck & Co., Inc., Novartis AG, Sunovion Pharmaceuticals, Inc., and Teva Pharmaceutical Industries Ltd.

Category:
  1. Introduction
  2. Executive Summary
    • Market Size Estimation (Revenue USD Million, 2014-2021)
    • Forecast Estimation (Revenue USD Million and CAGR%, 2017-2021)
  3. Research Methodology
  4. Market Landscape
    • Market Dynamics
      • Drivers
      • Barriers
      • Opportunities
    • Market Share Analysis
      • Companies
      • Drugs
    • Market Trends Analysis
      • Key success factors
      • Market Growth Rate
    • Market Attractiveness Analysis
    • Market Profitability Analysis
      • Buyer power
      • Supplier power
      • Barriers to entry
      • Threat of substitute products
      • Rivalry among firms in the industry
    • Distribution Channels
  5. Market Segmentation [refer Market Segments and Companies Tab]
    • Drug Class or Drug (Brand) Type
    • Drug or Disorder Test
    • Indication Type
    • Drug Treatment
    • Mechanism of Action
    • Therapeutic Area or Nature of Application
    • End User Groups
  6. Geography (Region, Country)
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Rest of the World (Middle East & Africa)
  7. Regulatory Overview 
    • IND, NDA filed, FDA, EMEA Approvals
  8. Pipeline Analysis(Phase 1, 2 and 3 Drugs)
    • Phase 3 Drugs Forecast Estimation (Approval to 2025)
    • Phase 1 and 2 Drugs – Qualitative Analysis
  9. Company Profiles [refer Market Segments and Companies Tab]
    • Company Overview
    • Financial Snapshot (FY 2014-2016)
    • Product Portfolio
    • Business Strategies
    • Recent Developments
  10. Recommendations
  11. References

Pulmonary Drugs Market

1. Drug Class
1.1. Anticholinergics
1.2. Antihistamines
1.3. Combination Drugs
1.4. Inhaled Corticosteroids (ICS)
1.5. Long-Acting Beta2-Agonists (LABA)
1.6. Short-Acting Beta2-Agonists (SABA)
1.7. Vasodilators
1.8. Others (Antibiotics, Antileukotrienes, Enzymes, MAbs, etc.)

2. Application
2.1. Allergic Rhinitis
2.2. Asthma & COPD
2.3. Cystic Fibrosis
2.4. Pulmonary Arterial Hypertension
2.5. Others

3. Distribution Channel
3.1. Drug Stores
3.2. E-commerce
3.3. Hospital Pharmacies
3.4. Retail Pharmacies

4. Geography (Region, Country)
4.1. North America (U.S., Canada)
4.2. Latin America (Brazil, Mexico, Rest of LA)
4.3. Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
4.4. Asia Pacific (Japan, China, India, Rest of APAC)
4.5. Rest of the World

5. Company Profiles
5.1. Actelion Pharmaceuticals, Inc.
5.2. AstraZeneca plc
5.3. Bayer AG
5.4. Boehringer Ingelheim GmbH
5.5. F. Hoffmann-La Roche Ltd.
5.6. GlaxoSmithKline plc
5.7. Merck & Co., Inc.
5.8. Novartis AG
5.9. Sunovion Pharmaceuticals, Inc.
5.10. Teva Pharmaceutical Industries Ltd.

Request market specific full ToC and sample pages for this report

Full Name*

Email*

Phone Number* [Please add country code]

Subject*

Message*